Vincerx Pharma (VINC) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company advancing therapies for cancer using a bioconjugation platform and small molecule drug program licensed from Bayer.

• Pipeline includes next-generation antibody-drug conjugates and small molecule-drug conjugates, targeting patient-specific cancer treatments.

• Formed through a business combination in December 2020, with principal offices in San Mateo, California.

Financial performance and metrics

• As of January 23, 2025, the last reported sale price of common stock was $0.1291 per share on Nasdaq Capital Market.

• Public float is below $75 million, limiting the amount of securities that can be sold in any 12-month period to one-third of the public float.

• No securities have been sold under the current shelf registration in the prior 12 months.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, capital expenditures, debt repayment, stock repurchases, and potential acquisitions or strategic investments.

• Pending use, proceeds may be invested in investment grade, interest-bearing securities.